Josh Bell

About Josh Bell

Senior development physician and portfolio leader with 15+ years of experience spanning clinicalcare, translational science, and global drug development. Proven track record leading multi-asset CNS portfolios, INDs, Phase 2–3 trials, and value-creating in-licensing transactions in epilepsy, neurovascular disease, movement disorders, sleep, neuromuscular disease, and pain. Deep expertise in biomarker-driven development, global regulatory strategy, governance, and investor engagement. Trusted matrix leader and executive-level decision partner.

Experience

1. Senior Director, Head, Translational Medicine

   Jazz Pharmaceuticals

   Apr 2023 — Present · Carlsbad, CA, US

   Leadership & Governance Senior R&D leader and standing member of enterprise governance bodies, including the Extended R & DLeadership Team (XLT) and Early Development Product Review Committee (EDPRC). Portfolio-level oversight across multiple CNS programs andFTEs, spanning epilepsy, sleep, movement disorders, and neuromuscular disease. Architect of global regulatory and development strategy, including accelerated approval pathways,with direct accountability to executive leadership and C-suite governance.Translational Medicine & Development Strategy Head, Translational Medicine, with therapeutic focus in epilepsy (DEE, focal, PGTC), sleep disorders,and neurodegenerative diseases (ALS, Parkinson’s disease, Huntington’s disease). Responsible for end-to-end translational strategy from candidate selection through proof-of-concept,leveraging advanced target-engagement and pharmacodynamic biomarkers including qEEG, TMSEEG/EMG, fMRI, volumetric MRI, PET, and soluble biomarkers.Broad scientific and medical leadership across the CNS TA inclusive of internal strategy, external innovation/out-licensing, and execution of early through late stage clinical programs, people managing and mentoring. Global clinical development lead for multiple CNS products, leading cross-functional teams, delivering 3 top line readouts in patients in 18 months.Clinical development lead for corporate development efforts in neuromuscular and peripheral nerve diseases (DM1, FSHD, ALS/FTD, PD, MG) as core member of neuroscience strategy team, global clinical lead for several in-licensing/acquisition diligences.

Education

• Columbia Business School Executive Education

  Foundations of Venture Capital

  2024 — 2024

• University of Toronto

  Doctor of Philosophy (PhD), Neurobiology and Neurosciences

• University of Toronto

  Doctor of Medicine (MD), Medicine

Skills

• Molecular Neuroscience
• Neuroscience
• Neurology
• Research
• Medicine
• Clinical Research
• Glutamate Receptors
• Public Health
• Anesthesiology
• Traumatic Brain Injury
• Molecular Biology